Literature DB >> 25319855

Accuracy of aPTT monitoring in critically ill patients treated with unfractionated heparin.

S van Roessel1, S Middeldorp, Y W Cheung, A H Zwinderman, A C J M de Pont.   

Abstract

INTRODUCTION: The anticoagulant effect of unfractionated heparin (UFH) is usually monitored by means of the activated partial thromboplastin time (aPTT). In critically ill patients, however, increased levels of acute phase proteins may decrease the accuracy of the aPTT, leading to inadequate UFH dosing. In these circumstances, the anti-Xa assay is recommended for monitoring.
OBJECTIVE: We aimed to analyse the accuracy of the aPTT for the monitoring of UFH dosing in critically ill patients.
METHODS: In critically ill patients treated with therapeutic doses of UFH, we compared aPTT levels with simultaneously measured anti-Xa levels as the gold standard. Sensitivity and specificity of the aPTT were determined for different cut-off points, receiver operating characteristic (ROC) curves were constructed and their areas under the curve (AUCs) were calculated.
RESULTS: A total of 171 paired blood samples from 58 patients were analysed. Concordant aPTT and anti-Xa values were observed in 108 (63.2%) data pairs. In 33 data pairs (19.3%) the aPTT was discordantly high and in 30 data pairs (17.5%) discordantly low. The sensitivity of the aPTT in detecting UFH underdosing and overdosing was 0.63 and 0.37, respectively. When considering alternative thresholds, ROC curves for underdosing and overdosing had AUCs of 0.71 and 0.81, respectively.
CONCLUSION: In this small cohort of critically ill patients, the aPTT was accurate in 63.2% of the blood samples. Its sensitivity to detect UFH underdosing and overdosing was low (0.63 and 0.37, respectively). We conclude that in critically ill patients, the aPTT is not accurate enough to detect UFH underdosing and overdosing.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25319855

Source DB:  PubMed          Journal:  Neth J Med        ISSN: 0300-2977            Impact factor:   1.422


  7 in total

1.  The impact of pharmacy monitoring and intervention in patients receiving intravenous heparin.

Authors:  Michaela C Lysogorski; Amany K Hassan; Stacie J Lampkin; Richard Geisler
Journal:  Int J Clin Pharm       Date:  2017-05-15

2.  Design and Implementation of an Anti-Factor Xa Heparin Monitoring Protocol.

Authors:  Tanya Williams-Norwood; Megan Caswell; Barbara Milner; Joseph C Vescera; Kelly Prymicz; Amy G Ciszak; Carol Ingle; Christopher Lacey; Evi X Stavrou
Journal:  AACN Adv Crit Care       Date:  2020-06-15

3.  Thromboembolic events and apparent heparin resistance in patients infected with SARS-CoV-2.

Authors:  Robert Beun; Nuray Kusadasi; Maaike Sikma; Jan Westerink; Albert Huisman
Journal:  Int J Lab Hematol       Date:  2020-06       Impact factor: 2.877

4.  Heparin dosage, level, and resistance in SARS-CoV2 infected patients in intensive care unit.

Authors:  Chiara Novelli; Erika Borotto; Ivo Beverina; Veronica Punzi; Danilo Radrizzani; Bruno Brando
Journal:  Int J Lab Hematol       Date:  2021-04-14       Impact factor: 3.450

5.  Monitoring of Unfractionated Heparin Therapy in the Intensive Care Unit Using a Point-of-Care aPTT: A Comparative, Longitudinal Observational Study with Laboratory-Based aPTT and Anti-Xa Activity Measurement.

Authors:  Benjamin Lardinois; Michaël Hardy; Isabelle Michaux; Geoffrey Horlait; Thomas Rotens; Hugues Jacqmin; Sarah Lessire; Pierre Bulpa; Alain Dive; François Mullier
Journal:  J Clin Med       Date:  2022-02-28       Impact factor: 4.241

Review 6.  Thromboprophylaxis with argatroban in critically ill patients with sepsis: a review.

Authors:  Mirjam Bachler; Lars M Asmis; Jürgen Koscielny; Thomas Lang; Hartmuth Nowak; Patrick Paulus; Jens-Christian Schewe; Christian von Heymann; Dietmar Fries
Journal:  Blood Coagul Fibrinolysis       Date:  2022-06-08       Impact factor: 1.061

7.  Anticoagulation Monitoring with Activated Partial ThromboPlastin Time and Anti-Xa Activity in Intensive Care Unit Patients: Interest of Thrombin Generation Assay.

Authors:  Paul Billoir; Thomas Elie; Jerrold H Levy; Emmanuel Besnier; Bertrand Dureuil; Benoit Veber; Véronique Le Cam-Duchez; Thomas Clavier
Journal:  Int J Mol Sci       Date:  2022-09-23       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.